Payment overview · 2025
General Payments
$583.11
25 reported records · 11 companies
Healthcare provider profile · identity verified
Jeffrey Brummer, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · EFFINGHAM, IL · NPI 1265417851
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Brummer, D.O. received $583.11 in general payments during 2025 across 25 reported records.
Organogenesis Inc. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $190.56 | 32.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.97 | 17.5% | 5 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $63.97 | 11.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.99 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.77 | 7.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.30 | 6.0% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $34.85 | 6.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.98 | 4.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.00 | 3.4% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $15.86 | 2.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.86 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $583.11 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $159.12 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.34 | 4 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $40.99 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $34.85 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| VARIVAX Normalized: varivax |
Biological | Merck Sharp & Dohme LLC | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| NUSHIELD Normalized: nushield |
Medical Supply | Organogenesis Inc. | $9.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 150 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 636 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 95 |
| Lisinopril | Lisinopril | 352 | 92 |
| Losartan Potassium | Losartan Potassium | 349 | 69 |
| Omeprazole | Omeprazole | 318 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 59 |
| Simvastatin | Simvastatin | 237 | 50 |
| Meloxicam | Meloxicam | 225 | 47 |
| Gabapentin | Gabapentin | 222 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 200 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 44 |
| Montelukast Sodium | Montelukast Sodium | 194 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 50 |
| Metformin Hcl | Metformin Hcl | 185 | 40 |
| Furosemide | Furosemide | 180 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 37 |
| Potassium Chloride | Potassium Chloride | 171 | 45 |
| Warfarin Sodium | Warfarin Sodium | 163 | 22 |
| Eliquis | Apixaban | 150 | 22 |
| Lorazepam | Lorazepam | 147 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 35 |
| Sertraline Hcl | Sertraline Hcl | 142 | 24 |
| Allopurinol | Allopurinol | 129 | 29 |
| Famotidine | Famotidine | 120 | 30 |
| Carvedilol | Carvedilol | 119 | 28 |
| Trazodone Hcl | Trazodone Hcl | 116 | 23 |
| Alprazolam | Alprazolam | 115 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 28 |
| Tramadol Hcl | Tramadol Hcl | 111 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 18 |
| Prednisone | Prednisone | 107 | 76 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 35 |
| Glipizide Er | Glipizide | 93 | 23 |
| Glipizide | Glipizide | 89 | 24 |
| Metformin Hcl Er | Metformin Hcl | 86 | 21 |
| Clonazepam | Clonazepam | 85 | suppressed |
| Xarelto | Rivaroxaban | 85 | 13 |
| Donepezil Hcl | Donepezil Hcl | 82 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 18 |
| Memantine Hcl | Memantine Hcl | 80 | 11 |
| Januvia | Sitagliptin Phosphate | 74 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 27 |
| Fenofibrate | Fenofibrate | 72 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 70 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 12 |
| Atenolol | Atenolol | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Cefdinir | Cefdinir | 48 | 34 |
| Ozempic | Semaglutide | 47 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 12 |
| Valacyclovir | Valacyclovir Hcl | 39 | 12 |
| Nabumetone | Nabumetone | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Euthyrox | Levothyroxine Sodium | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Estradiol | Estradiol | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $583.11 · 25 records | Organogenesis Inc. | ACTIV.A.C., APLIGRAF, CAPVAXIVE, COLLAGENASE SANTYL, ELIQUIS, ENFLONSIA, Flexitouch Plus, GRAFIX PL, JARDIANCE, NURTEC ODT, NUSHIELD, NUZYRA, Nimbl, PURAPLY WOUND MATRIX, ROTATEQ, VARIVAX, VAXELIS, VAXNEUVANCE, VRAYLAR, VYNDAMAX, Wegovy, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error